Introductory paper: High-dose influenza vaccine.
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
02
06
2020
accepted:
01
09
2020
pubmed:
8
2
2021
medline:
25
5
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
Seasonal influenza has a significant impact on global public health each year, especially in older adults 65 years of age and above. This paper presents the evolution of high-dose influenza vaccine and the quantity as well as quality of evidence on this vaccine. Its introduces other peer-reviewed manuscripts included in this supplement covering the benefits high-dose influenza vaccine over ten consecutive influenza seasons. The development of the high-dose influenza vaccine represents an important step in the evolution of influenza vaccines, offering an advancement in prevention of influenza and a step in encouraging healthy aging in older adults. A video summary of the article can be accessed via the Supplementary data link at the end of this article.
Identifiants
pubmed: 33549389
pii: S0264-410X(20)31147-6
doi: 10.1016/j.vaccine.2020.09.005
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Editorial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
A1-A5Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest MD, LJC, BS, CR, AC, MM, DPG, RH, and SIS are employees of Sanofi Pasteur.